AI assistant
Replimune Group, Inc. — Director's Dealing 2022
Apr 5, 2022
33193_dirs_2022-04-05_779a8aa5-94ea-4164-ad89-3f94b8eac062.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2022-04-01
Reporting Person: Rhodes Jason P (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-04-01 | Stock Option (right to buy) | $18.26 | A | 16500 | Acquired | 2032-04-01 | Common Stock (16500) | Direct |
Footnotes
F1: This option was granted on April 1, 2022 with respect to 16,500 shares of the Issuer's common stock and vests in full on April 1, 2023.
F2: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.